1. Introduction {#sec1}
===============

Atherosclerosis is the primary cause of coronary heart disease (CHD) and of peripheral arterial occlusive disease (PAOD), being one of the most common causes for disease and death throughout the world \[[@B1]\]. It has been found that the adipose tissue is connected with the pathogenesis of atherosclerosis as a result of a secretion of a multitude of pro- and antiatherogenic cytokines and adipokines such as adiponectin, leptin, resistin, and acute-phase proteins \[[@B2]\]. These adipokines play a central role in the pathogeny of the metabolic syndrome \[[@B3], [@B4]\] and in the development of systemic inflammation \[[@B5], [@B6]\].

The serum levels of adiponectin, potential mediator of atherosclerosis, are significantly low in the case of patients with visceral obesity and insulin-resistance as well as in the case of type 2 diabetes mellitus \[[@B4], [@B6], [@B7]\]. The low levels of adiponectin were associated with the presence of CHD \[[@B6], [@B8]\] and appear to be a risk factor for CHD \[[@B6], [@B9]\].

Besides adiponectin, the adipokines intensely produced by the adipose tissue are leptin and resistin. The physiological role of leptin is very complex; it could be an important mediator of the relationship among obesity, overweight, and atherosclerosis \[[@B3], [@B5]\]. Resistin, also involved in endothelial dysfunction, expressed primarily in inflammatory cells, suggests a potential role in atherosclerosis \[[@B10], [@B11]\]. However, the relationship between resistin and inflammation, insulin resistance, and atherosclerosis in humans remains unexplored. Tumor necrosis factor-*α* (TNF-*α*), a pleiotropic proinflammatory cytokine, has been also recognized in human atheroma \[[@B12]\].

Adiponectin, leptin, and resistin are adipocytokines that control body weight, and insulin sensitivity \[[@B13]\]. These adipokines have been investigated in relation to obesity, metabolic syndrome, insulin resistance, and other pathological conditions and processes. In addition, it is now established that adipokines play a role in the maintenance of an inflammatory state in adipose tissue and in the development of obesity and comorbidities \[[@B14]\].

It has become increasingly evident that white adipose tissue-derived cytokines mediate between obesity-related exogenous factors and the molecular events that lead to metabolic syndrome, inflammation, and cardiovascular diseases \[[@B15]\]. Although there are studies which demonstrate the relationship between adipokines, obesity, and increased risk of cardiovascular events \[[@B14]--[@B16]\], their interplay is still poorly studied.

The hypothesis of the study starts from the assumption that among people aged over 55 atherosclerotic PAOD is a known indicator of systemic atherosclerotic disease \[[@B17]\] and literature in this area is scarce \[[@B18]--[@B20]\]. The role of adiponectin in the initiation and development of atherosclerotic lesions in PAOD patients has been studied and analyzed very little so far \[[@B21]\]. At the same time remains unexplored the role of leptin and resistin in PAOD. In the absence of data on relationship between adipokines and atherosclerotic PAOD, we have decided to undertake the present study.

The aim of our study was to assess the serum levels of adipokines (adiponectin, leptin, resistin, and TNF-*α*) in patients with PAOD caused by atherosclerosis. Furthermore, the link between serum levels within investigated adipokines on one hand and between adipokines and cholesterol, HDL cholesterol, triglycerides, glycemia, fibrinogen, or CRP (C reactive protein), smoking, obesity, arterial hypertension, type II diabetes mellitus, coronary heart disease on the other hand was investigated.

2. Materials and Methods {#sec2}
========================

2.1. Study Protocol {#sec2.1}
-------------------

A prospective case-control study was carried out at the Surgical Clinic No. 2 of the County Clinical Hospital of Cluj-Napoca, Romania, from January 2009 to January 2011.

The case group included patients with PAOD caused by atherosclerosis, diagnosed by duplex scanning, based on an ankle-brachial index (ABI) \< 0.9. The ankle-brachial index was calculated by dividing the ankle systolic pressure measured at the malleolar level with a blood pressure cuff, to the higher of the two brachial pressures.

Patients with terminal diseases (e.g., cardiovascular failure, hepatic or renal failure, etc.) were excluded from the case group. Only the patients who agreed to participate in the study were included.

The control group included matched patients from our outpatients referred to us for lower limb chronic venous insufficiency problems, general surgery conditions (e.g., appendicitis, hernia, cholecystitis, etc.), or hospital staff and their relatives that presented an ABI \> 0.9. The subjects included in this group had no known history of autoimmune diseases, neoplasia, cardiovascular failure, and hepatic or renal failure.

The study was approved by the Local Ethics Committee (both University\'s and Hospital\'s) and was conducted according to the Helsinki Declaration of 1964 as revised in 1983. Each subject included in the study (both case and control group) signed a written informed consent for their participation in the study. All subjects participated voluntary and the confidentiality of all data was respected.

The following data were collected for both groups: measurements of basic constituents (age, weight, height, and distal arterial pressures), medical history (arterial hypertension (AHT), type II diabetes mellitus (DM), coronary heart disease (CHD)), and drug use (e.g., actual or former smoking habit---more than 10 cigarettes/day and alcohol abuse). From each subject included in the study, we obtained a blood sample and determined the following parameters: cholesterol, triglycerides, fibrinogen, high-density lipoprotein (HDL), glycemia, creatinine, adiponectin, leptin, resistin, TNF-*α*, and C reactive protein (CRP). To all subjects included in the study the blood samples were collected after an overnight fast, in the morning between 7 and 9 AM. Plasma concentrations of glucose, creatinine, lipids, and lipoproteins were determined using standard enzymatic colorimetric methods. Normal serum concentration of CRP was considered normal at values lower than 1 mg/dL. Total cholesterol \> 200 mg/dL was used as a cutoff value for the lipid profile according to Adult Treatment Panel III guidelines \[[@B22]\].

Circulating plasma levels of adiponectin, leptin, resistin and TNF-*α* were measured by a commercially available enzyme-linked immunosorbent assay (ELISA), using Quantikine reagents (R&D Systems): Human Adiponectin, Human Leptin, Human Resistin, and Human TNF-*α*/TNFSF1A.

Body mass index (BMI) was calculated according to Quetelet\'s formula: weight (kg)/height (m^2^) \[[@B23]\]. The following classification of subjects according to BMI was applied to both case and control group: BMI \< 25 kg/m^2^ = normal, 25 ≤ BMI \< 30 kg/m^2^ = overweight, and BMI ≥ 30 kg/m^2^ = obese (over 40, morbidly obese). Patients were considered as hypertensive according to Joint British Societies\' guidelines, patients with systolic blood pressure higher than 140 mmHg or with diastolic blood pressure higher than 90 mmHg, or both \[[@B24]\]. Coronary heart disease (CHD) was defined by standard Framingham Heart Study criteria as any of new-onset angina, coronary insufficiency, or fatal or nonfatal myocardial infarction \[[@B25]\]. Diabetes mellitus (DM) was defined according to the American Diabetes Association as follows: any patient with two fasting plasma glucose levels of 126 mg/dL (7.0 mmol/L) or higher, or treatment with blood glucose-lowering drugs \[[@B26]\].

2.2. Statistical Analysis {#sec2.2}
-------------------------

Descriptive statistics for quantitative data were expressed as mean, standard deviation, and 95% confidence intervals whenever the data were normal distributed. Otherwise, the median was used. The comparisons between groups for quantitative data were carried out with Student\'s *t*-test when data were normally distributed; otherwise the Mann-Withney test was applied.

Qualitative variables were summarized as absolute frequency, percentages and associated 95% confidence intervals. The 95% confidence interval was calculated based on optimized binomial distribution formula \[[@B27], [@B28]\]. Comparison between two proportions was performed by applying the *Z*-test. Statistical analysis was carried out with SPSS v. 16; all tests were applied at a significance level of 5%.

The link between the investigated adipokines and cholesterol, HDL cholesterol, triglycerides, glycemia, fibrinogen, or CRP was investigated using Pearson correlation coefficient if experimental data proved to be normally distributed; otherwise Spearman correlation coefficient was used. The link between the investigated adipokines and the qualitative variables (such as obesity, AHT (yes/no), DM (yes/no), CHD (yes/no), and smoking (yes/no)) was carried out by applying the Spearman\'s rank correlation coefficient. The power of the correlation was interpreted according to Colton rules \[[@B29]\]. A correlation coefficient was considered statistically significant when the *P* value was smaller than 0.05.

3. Results {#sec3}
==========

3.1. Studied Groups {#sec3.1}
-------------------

One hundred and forty patients, 26 females (18.6%, 95%CI (12%--26%)) and 114 males (81.4%, 95%CI (74%--88%)), met the inclusion criteria and were studied in the case group. Eighty-one patients, 17 females (21%, 95%CI (12%--31%)) and 64 males (79%, 95%CI (69%--88%)), were included in the control group. No statistically significant difference was identified between the proportion of females in both case and control group (*P* = 0.6647).

The mean age in the case group was of 65.25 ± 10.84 years (95%CI (63.44--67.06)), with a median of 65.50. A statistically significant age difference was identified between the female patients (70.35 ± 10.33, 95%CI (66.18--74.52), median = 72) and the male patients (64.09 ± 10.66, 95%CI (62.11--66.07)) in the case group (Mann-Withney statistics = 989, *P* = 0.0082).

The mean age of control group was of 60.83 ± 10.60 years (95% CI (58.48--63.17)), with a median of 60. No statistically significant age difference was identified between the female population (65.06 ± 10.87, 95%CI (59.47--70.650), median = 68) and the male population (59.70 ± 10.33, 95%CI (57.12--62.28)) in the control group (Mann-Whitney statistics = 412, *P* = 0.1258).

A statistically significant difference regarding the age of the subjects in the case and control group was identified (Mann-Whitney statistics = 4320, *P* = 0.0032).

The mean of BMI of case group was of 26.54 ± 4.58 (*n* = 140); the mean of BMI of control group was of 26.23 ± 4.64. No statistically significance difference regarding the BMI between the case and the control group was identified (Student\'s *t*-test = 0.483, df (degrees of freedom) = 219, *P* value = 0.629).

3.2. Case versus Control Comparison {#sec3.2}
-----------------------------------

The comparison between case and control featuring number of patients, percentages, and associated *Z*-scores considering associated diseases is presented in [Table 1](#tab1){ref-type="table"}.

The biochemical characteristics of both case and control group are presented in [Table 2](#tab2){ref-type="table"}.

The serum levels of the inflammation parameters synthesized by the adipose tissue determined by the described immunological techniques are presented in [Table 3](#tab3){ref-type="table"}.

Adiponectin presented statistically significant (*P* = 0.0061, [Table 3](#tab3){ref-type="table"}) lower levels in PAOD patients (2380.23 ± 1634.42 pg/mL) than in control group patients (3065.06 ± 1901.2 pg/mL). The serum levels of leptin, resistin, and CRP proved to be also statistically significant higher in the case group compared to the control group (*P* \< 0.05, [Table 3](#tab3){ref-type="table"}).

The serum levels of leptin and resistin were also monitored, levels which had higher mean values in PAOD patients compared to control group patients, hence the statistically significant differences ([Table 3](#tab3){ref-type="table"}).

TNF-*α* did not present significant differences between the two investigated groups ([Table 3](#tab3){ref-type="table"}).

The graphical representation of the ranges associated to the markers of the inflammation secreted by the adipose tissue is presented in Figures [1(a)](#fig1){ref-type="fig"}--[1(d)](#fig1){ref-type="fig"}.

Eighty patients (24 from case group and 65 from control group) had the TNF-*α* over the normal value. Out of these patients, almost 73% were normal weighted or overweighed, 27% were obese.

The correlation analysis carried out on adipokines identified the following statistically significant correlations; the results are presented in [Table 4](#tab4){ref-type="table"}.

All other correlations within adipokines and between adipokines and all investigated variables did not prove to be statistically significant (*P* \> 0.05).

4. Discussion {#sec4}
=============

The levels of adipokines (adiponectin, leptin, resistin, and TNF-*α*) in patients with PAOD caused by atherosclerosis were successfully investigated. The group of PAOD patients was compared to a control group. The sampling of the patients in both case and control group was as accurate as possible. Unfortunately, statistically significant differences were identified for the following variables: age, AHT, and CHD. The age of the patients in case and control group proved to be a statistically significant difference, but this variable did not affect the results of our study since in the medical specialty literature no statistically significant difference in adipokines level was reported \[[@B30]\]. No statistically significant difference was identified between the two studied groups for BMI. The presence of a statistically significant difference between groups in terms of BMI could be considered a bias factor since the medical specialty literature proved an inverse correlation between adiponectin and fat mass \[[@B31]\].

The absence of a statistically significant difference in the proportion of genders between groups proves the proper assignment of patients in the groups. A higher statistically significant proportion of patients from our case group proved to have had AHT compared to control group (*P* \< 0.05, see [Table 1](#tab1){ref-type="table"}) \[[@B32]\]. Moreover, a higher statistically significant proportion of patients from the case group proved to have had CHD compared to the control group (*P* \< 0.05, see [Table 1](#tab1){ref-type="table"}) \[[@B11], [@B32]--[@B34]\].

The absence of a statistically significant difference between the percentages of diabetes mellitus in both case and control groups confirms the reliability of our results, knowing that this disease is an important risk factor for large vessel atherosclerotic occlusive disease \[[@B10], [@B32]\]. Furthermore, even if smoking was identified as being closely linked to PAOD, a relation first identified by Erb in 1911 \[[@B34]--[@B36]\], the distribution of smoking in our group\'s patients did not prove to be statistically significant different (*P* = 0.0545, see [Table 1](#tab1){ref-type="table"}). The groups under investigation were homogeneous as far as the demographic data and clinical characteristics were concerned, except for the age variable and the associated cardiovascular diseases.

Hyperlipidemia has been associated with an increased rate of lower extremity occlusive disease (*P* = 0.049, [Table 2](#tab2){ref-type="table"}), and our results were according to the data published by the medical specialty literature \[[@B37]\]. Even if some studies identified the cholesterol serum level as an important independent risk factor, in our study it was not associated with PAOD \[[@B36]\].

No statistically significant differences could be identified for cholesterol, HDL, Creatinine, and glucose serum levels ([Table 2](#tab2){ref-type="table"}).

The fibrinogen proved to be statistically different in our study when the two investigated groups were compared (higher values in the case group compared to control group, *P* \< 0.05, see [Table 2](#tab2){ref-type="table"}).

Another acute phase protein, CRP, which normally increases not only in infections but also in activations of certain chronic diseases, was also significantly higher in the investigated PAOD patients (*P* \< 0.05, [Table 3](#tab3){ref-type="table"}).

In our study the serum values of adiponectin were significantly lower in the case group than the values of the control group ([Table 3](#tab3){ref-type="table"}). This result could indicate that hypoadiponectinemia is related to the development of PAOD. Since that low levels of adiponectin are correlated to endothelial dysfunction \[[@B38]\], the results of our study suggest that hypoadiponectinemia can be used as a marker of atherosclerosis. Because almost a third of patients included in the study were obese or diabetic, further studies on larger sample size must be carried out for the association between adipokines and CRP and PAOD in the nonobese/diabetic population.

With regard to the role of leptin in the development of atherosclerotic lesions in PAOD, our study has indicated significantly increased serum levels in these patients compared to control group (*P* \< 0.05, [Table 3](#tab3){ref-type="table"}). Knowing its proatherogenic function, correlated with the increased values that we had detected, recommends this parameter as a possible biomarker of atherosclerosis with peripheral vascular localizations \[[@B39]--[@B41]\].

The mean values of resistin presented significantly higher values in PAOD patients compared to the patients in the control group, and this fact suggested its possible participation in the process of atherogenesis (*P* \< 0.05, [Table 3](#tab3){ref-type="table"}). As far as we know there are no published data available to appreciate the role of resistin in the case of PAOD; therefore more studies are required.

A series of positive or negative significant correlations were identified between certain adipokines and some of the investigated parameters (see [Table 4](#tab4){ref-type="table"}) but all these correlations proved to be weak. Leptin proved to be significantly related with triglyceride serum level, positively for case group and negatively for control group. Adiponectin proved to be significantly related with AHT, positively for case group and negatively for control group. In our study, adipokine levels did not prove to be related to obesity or to BMI, a fact contradicted by some studies \[[@B31]\]. Adiponectin and leptin proved to be significantly related to TNF-*α* in control group and obesity was also related to TNF-*α* ([Table 4](#tab4){ref-type="table"}), confirming data from the literature \[[@B7], [@B8], [@B42]\].

The weak negative relationship (*P* \< 0.05, [Table 4](#tab4){ref-type="table"}) between TNF-*α* and adiponectin confirmed the already known antagonistic effect of the adiponectin on the TNF-*α* activity \[[@B43]--[@B46]\].

Study Strengths and LimitationsAdipokines expression has been extensively studied in cardiovascular disease but all studies have been performed either on patients with typical ischaemic heart disease or in hypertensive patients \[[@B10]--[@B12], [@B15]\]. However, except for a recent report by Dieplinger et al. \[[@B21]\], there had been no other data on adipokines expression in PAOD. More important, Dieplinger et al. \[[@B21]\] studied only adiponectin expression in PAOD and the results are similar to our findings. This is a pilot study designed to assess if inflammatory and metabolic mediators can be used as potential atherosclerotic biomarkers in PAOD patients. Here, we have showed that serum adiponectin, resistin, and leptin might have a potential role in developing atherosclerotic lesions in patients with PAOD. Further experimental and clinical studies are required to establish the exact role of adipokines in the disease development and to provide a definite answer to the question of whether measuring these chemokines could be used for the follow-up of PAOD patients.

5. Conclusion {#sec5}
=============

The markers of the inflammation secreted by the adipose tissue (adiponectin, leptin, resistin, CRP) showed significant differences in case group patients (with PAOD) compared to control group. Our results point out the possible role of hypoadiponectinemia in developing PAOD. Proinflammatory cytokines produced by white adipose tissue (resistin and leptin) are likely to be promising targets for controlling the reduction of inflammation in order to prevent the progression of early or already established atherosclerotic lesions in PAOD patients, but further research is, however, necessary.
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###### 

Associated diseases: comparison between case and control group.

                   Group         *Z*-test to compare             
  ---------------- ------------- --------------------- --------- ----------
  Obesity          33 (23.57)    24 (29.63)            −0.9613   0.3364
  DM               45 (32.14)    27 (33.33)            −0.1528   0.8786
  AHT              95 (67.86)    39 (48.15)            2.9374    0.0033
  CHD              106 (75.71)   31 (38.27)            5.8555    \<0.0001
  Smoking status   97 (69.29)    45 (55.56)            1.9231    0.0545

^a^: sample size case group = 140 patients; ^b^: sample size control group = 81 subjects; DM: Diabetes mellitus; AHT: arterial hypertension; CHD: coronary heart disease.

###### 

Biochemical data for PAOD patients and controls.

                                       Group            Mann-Whitney test          
  --------------------- -------------- ---------------- ------------------- ------ --------
  Cholesterol (mg/dL)   Mean ± StDev   201.54 ± 49.23   189.48 ± 55.12      4869   0.0803
  Median                193.00         190.00                                      
                                                                                   
  TG (mg/dL)            Mean ± StDev   130.62 ± 56.97   116.81 ± 52.01      4769   0.0490
  Median                117.00         105.00                                      
                                                                                   
  HDL (mg/dL)           Mean ± StDev   48.23 ± 13.01    46.65 ± 11.57       5295   0.4120
  Median                48.00          46.00                                       
                                                                                   
  Creatinine (mg/dL)    Mean ± StDev   0.89 ± 0.21      0.84 ± 0.21         4829   0.0614
  Median                0.90           0.90                                        
                                                                                   
  Glycemia (mg/dL)      Mean           99.97 ± 22.63    98.32 ± 18.04       5494   0.7006
  Median                94.00          95.00                                       
                                                                                   
  Fibrinogen (mg/dL)    Mean           341.66 ± 84.07   318.68 ± 72.20      4725   0.0390
  Median                338.00         311.00                                      

TG: triglycerides; HDL: high-density lipoprotein; StDev: Standard deviation.

###### 

Serum concentrations of the studied parameters in the different studied groups.

                                       Group               Mann-Whitney test          
  --------------------- -------------- ------------------- ------------------- ------ --------
  Adiponectin (pg/mL)   Mean ± StDev   2380.23 ± 1634.42   3065.06 ± 1901.2    4415   0.0061
  Median                2170.00        2536.00                                        
                                                                                      
  Leptin (pg/mL)        Mean ± StDev   2844.42 ± 3301.08   2047.81 ± 3301.08   4695   0.0332
  Median                1515.00        1254.00                                        
                                                                                      
  Resistin (pg/mL)      Mean ± StDev   16.14 ± 10.68       13.84 ± 11.20       4706   0.0352
  Median                13.75          12.00                                          
                                                                                      
  TNF-*α* (pg/mL)       Mean ± StDev   4.96 ± 5.18         5.11 ± 6.01         5540   0.7756
  Median                3.30           2.90                                           
                                                                                      
  CRP (mg/dL)           Mean ± StDev   0.82 ± 0.45         0.62 ± 0.41         4131   0.0008
  Median                0.80           0.50                                           

TNF-*α*: tumor necrosis factor-*α*; CRP: C reactive protein; StDev: standard deviation.

###### 

The results of correlation analysis.

  Variables                         Correlation          
  --------------------------------- ------------- ------ --------
  Case group                                             
   TNF-*α* versus DM                Positive      Weak   0.0341
   Resistin versus AHT              Negative      Weak   0.0080
   Adiponectin versus AHT           Positive      Weak   0.0313
   Leptin versus cholesterol        Positive      Weak   0.0437
   Leptin versus triglycerides      Positive      Weak   0.0090
  Control group                                          
   TNF-*α* versus obesity           Negative      Week   0.0468
   TNF-*α* versus adiponectin       Negative      Weak   0.0222
   TNF-*α* versus leptin            Positive      Weak   0.0255
   Leptin versus triglycerides      Negative      Weak   0.0238
   Adiponectin versus AHT           Negative      Weak   0.0359
   Obesity versus HDL cholesterol   Positive      Week   0.0342

Week correlation was considered whenever the correlation coefficient was between \[−0.5; 0.5\].
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